MARKET

AMAG

AMAG

AMAG
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.93
-0.11
-1.22%
After Hours: 8.93 0 0.00% 16:00 09/25 EDT
OPEN
8.99
PREV CLOSE
9.04
HIGH
9.33
LOW
8.91
VOLUME
330.43K
TURNOVER
--
52 WEEK HIGH
13.53
52 WEEK LOW
4.410
MARKET CAP
307.90M
P/E (TTM)
-1.1698
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
AMAG Pharmaceuticals to Participate in H.C. Wainwright 22nd Annual Global Investment Conference
WALTHAM, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that Scott Myers, Chief Executive Officer, and Brian Piekos, Chief Financial Officer, will participate in a fireside chat at the H.C. Wainwright 22nd Annual Global Investment Conference on Tuesday
GlobeNewswire · 09/09 12:00
AMAG Pharmaceuticals (AMAG) Down 0.4% Since Last Earnings Report: Can It Rebound?
AMAG Pharmaceuticals (AMAG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · 09/05 15:31
AMAG Pharmaceuticals stock price target raised to $10 from $7 at Truist
AMAG | Complete AMAG Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
marketwatch.com · 08/19 11:05
AMAG Pharmaceuticals, Inc. (AMAG) CEO Scott Myers on Q2 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 08/09 07:31
AMAG Pharmaceuticals' (AMAG) Q2 Loss Narrower Than Expected
AMAG (AMAG) posts a narrower-than-expected loss and revenues miss estimates in the second quarter of 2020.
Zacks · 08/07 14:45
AMAG Pharmaceuticals (AMAG) Reports Q2 Loss, Lags Revenue Estimates
AMAG Pharmaceuticals (AMAG) delivered earnings and revenue surprises of 16.67% and -6.61%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/06 13:55
AMAG Pharmaceuticals Announces Second Quarter 2020 Financial Results and Provides Corporate Update
Financial guidance reissued to include EBITDA-positive projection for second-half 2020 Strategic shift and momentum build through recent business development activitiesBrian Piekos promoted to Chief Financial OfficerConference call scheduled for 8:00 a.m. ET
GlobeNewswire · 08/06 11:00
AMAG Pharmaceuticals (AMAG) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
AMAG Pharmaceuticals (AMAG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 07/30 16:33
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AMAG. Analyze the recent business situations of AMAG through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AMAG stock price target is 9.50 with a high estimate of 14.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 196
Institutional Holdings: 47.09M
% Owned: 136.58%
Shares Outstanding: 34.48M
TypeInstitutionsShares
Increased
24
1.05M
New
32
553.91K
Decreased
50
2.72M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.88%
Pharmaceuticals & Medical Research
+1.58%
Key Executives
Chairman/Independent Director
Gino Santini
President/Chief Executive Officer/Director
Scott Myers
Chief Financial Officer
Brian Piekos
Chief Operating Officer/Executive Vice President
Anthony Casciano
Chief Human Resource Officer/Senior Vice President
Kelly Schick
Senior Vice President/Director of Sales/Director of Marketing
Tony Casciano
Executive Vice President/General Counsel/Secretary
Joseph Vittiglio
Vice President
Nancy Griffith
Independent Director
John Fallon
Independent Director
Paul Fonteyne
Independent Director
David Johnson
Independent Director
Cooper Russell
Independent Director
Kathrine O'Brien
Independent Director
Anne Phillips
Independent Director
Davey Scoon
Independent Director
James Sulat
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About AMAG
AMAG Pharmaceuticals, Inc. is a pharmaceutical company. The Company's segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse. It is engaged in the development of Digoxin immune fab, a polyclonal antibody for the treatment of severe preeclampsia in pregnant women. Makena is a drug indicated to reduce the risk of preterm birth in women pregnant with a single baby having a history of singleton spontaneous preterm birth.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of AMAG Pharmaceuticals, Inc. stock information, including NASDAQ:AMAG real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AMAG stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AMAG stock methods without spending real money on the virtual paper trading platform.